Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03337113
Other study ID # 1705-003
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 5, 2018
Est. completion date January 31, 2021

Study information

Verified date April 2022
Source Kent State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Smoking remains the leading cause of preventable death in the United States, and current first-line treatments leave the majority of tobacco dependent individuals unable to quit. The inability to quit despite motivation to do so, is thought to result in part, from self-control failure. Working memory (WM) deficits contribute to imbalanced self-control and allow automatic impulses to drive behavior. Thus, WM plays a critical role in addictive behavior, and is particularly relevant to smoking. Indeed, a strong link between WM and smoking has been established in the literature; most notably, degree of WM impairment and deficits in activation in associated brain regions predict time to relapse, and WM moderates the relationship between craving and relapse. Given these insights, researchers have been examining interventions that may target WM including WM training (WMT) and repetitive Transcranial Magnetic Stimulation (rTMS). WMT involves taxing this executive function repeatedly over time and has shown positive preliminary results in improving measures of self-control and reducing consumption of addictive substances. Similarly, rTMS, a non-invasive brain stimulation procedure that stimulates neuronal tissues and increases cortical excitability, has been shown to increase WM capacity and reduce craving and consumption of several addictive substances including nicotine. While these interventions have demonstrated initial promise in affecting addictive behaviors, the magnitude and durability of their effects may be limited. Recently, researchers have posited - but not yet empirically tested - that WMT administered in combination with rTMS may result in an additive or supra-additive effect in treating addictive processes. This is highly significant; the clinical utility of rTMS over current first line treatments may be limited if factors with potential to enhance its effectiveness are not examined. Given these recent advances in the literature, the primary objective of the proposed study is to evaluate the individual and combined effects of Working Memory (WM) training and repetitive Transcranial Magnetic Stimulation (rTMS) on WM performance and smoking behaviors as well as critical mediators of these effects. These aims will be examined in a sample of tobacco dependent adults (N=130) utilizing a 2x2 factorial experimental design including four groups (WMT+rTMS, sham WMT+rTMS, WMT+sham TMS, and sham WMT+sham rTMS) capable of isolating independent and combined effects of WMT and rTMS.


Description:

SPECIFIC AIMS Smoking remains the leading cause of preventable death in the U.S. Current first line treatments leave approximately 70% of tobacco dependent individuals unsuccessful in their attempt to quit. Specifically, only 5-30% of those who initiate treatment, including intensive first-line interventions, are able to maintain abstinence for one or more years. The inability to quit despite motivation to do so is thought to result, in part, from self-control failure and can be understood within the framework of dual process models of addiction. Dual process models view vulnerability to tobacco dependence as the relative balance between automatic impulses and control processes orchestrated through the interplay of multiple executive function. Working memory (WM) is an executive function associated with updating information to solve immediate problems, and achieve current goals. WM is a key cognitive process underlying the regulatory control component of dual process models and is involved in the initiation, maintenance, and relapse stages of tobacco dependence. Most notably, deficits in WM performance and activation in associated brain regions predict time to relapse and strong WM has been shown to reduce the effect of craving on the ability to resist smoking. Given this relationship, individuals with tobacco dependence are likely to benefit from interventions that strengthen WM. Recently, several studies have demonstrated that increasing WM capacity through WM training (WMT) is associated with positive outcomes in several populations with substance use or impulse control disorders. Specifically, studies have demonstrated that WMT is associated with decreased: delay discounting in substance users, weight re-gain after a weight loss program, and alcohol use in heavy drinkers. A second emerging innovation in the treatment of addictions is repetitive Transcranial Magnetic Stimulation (rTMS), a procedure which sends magnetic pulses through the scalp to stimulate neuronal tissue resulting in observed changes in neuronal plasticity and striatal dopamine. rTMS has now demonstrated positive effects in several substance use disorders including nicotine, alcohol, and stimulant dependence. This procedure has been shown to be effective in reducing smoking urges in abstinent as well as satiated smokers and to reduce cigarette consumption. While promising results for this treatment have been demonstrated, the size and durability of the therapeutic effect may be limited. Additionally, the mechanism by which rTMS exerts positive effects on smoking outcomes is unknown. Recently it has been posited that changes in WM performance resulting from rTMS may be the key pathway to its observed effects on smoking related outcomes, and furthermore that WMT administered in close temporal precedence to rTMS may result in an additive or supra-additive effect in treating addictive processes. However, these hypotheses have not been tested to date despite their importance for understanding and improving the clinical impact of these emerging therapeutic modalities for treating addictive behaviors. Interventions with the ability to effectively target self-control processes fill in a critical gap in currently available treatment options. The primary objective of the proposed study is to evaluate the potential for improved effects and examine mediating pathways of WMT in combination with rTMS on a laboratory based smoking task and neuropsychological measures of WM performance. These aims will be examined in a sample of tobacco dependent adults (N=130) utilizing a 2x2 factorial design including four groups (WMT+rTMS, sham WMT+rTMS, WMT+sham TMS, and sham WMT+sham rTMS) capable of isolating independent and combined effects of WMT and rTMS. The study will include a baseline laboratory assessment, 10 WMT sessions over two weeks, followed by 10 days of WMT immediately preceding and following brain stimulation sessions (10 Hz rTMS, 2000 pulses per session, applied to left DLPFC). Neurocognitive and psychological mediators will be assessed between baseline and final laboratory assessment. Lastly, a follow-up assessment will occur one-month after the final laboratory visit. The proposed study will test the following Specific Aims: Aim 1: To test the potential for improved effects of combining WMT with rTMS on smoking behaviors as compared to the independent effects of either condition alone. Hypothesis: Single active conditions (WMT+sham rTMS and sham WMT+rTMS) will result in significant increases in time to lapse on an analogue task as compared to the double sham condition (sham WMT+sham rTMS), and the WMT+rTMS condition will result in significant increases in time to lapse as compared to the single active conditions. Aim 2: To test the potential for improved effects of combining WMT with rTMS on WM performance. Hypothesis: WMT + rTMS will result in significant increases in WM performance as compared to all other conditions, including the additive increases in conditions outlined in Aim 1. Aim 3: To test mediating pathways of the effects rTMS on smoking behaviors including changes in craving, mood, and WM performance. Hypothesis: The direct effect of rTMS on smoking outcomes will be mediated by gains in WM performance, and this effect will be largest in the WMT+rTMS condition.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date January 31, 2021
Est. primary completion date January 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - meet safety guidelines for application of rTMS - be 18-60 years of age - have smoked cigarettes regularly for at least one year - currently smoke at least 10 cigarettes per day - have a carbon monoxide (CO) level >10 ppm - currently use no other nicotine products regularly Exclusion Criteria: - meet criteria for current alcohol or substance dependence - have a current affective disorder (depression, dysthymia, or mania) or psychotic symptoms - are currently pregnant or lactating, or intend to become pregnant - have a health condition for which rTMS is contraindicated

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Working Memory Training
The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
Sham Working Memory Training
In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
Device:
repetitive Transcranial Magnetic Stimulation
The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard "F3" location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application.
Sham repetitive Transcranial Magnetic Stimulation
Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.

Locations

Country Name City State
United States Brown University Providence Rhode Island
United States Butler Hospital Providence Rhode Island

Sponsors (3)

Lead Sponsor Collaborator
Kent State University Brown University, Butler Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Lapse on a Smoking Lapse Analogue Task The Delay to Smoking Analogue Task is a behavioral choice paradigm that is sensitive to smoking medication effects in which participants earn monetary rewards for delaying initiation of cigarette smoking in 5-minute increments over a 50-minute period, following 3-hours of observed smoking deprivation. Range = 0 - 50 minutes. Higher scores indicate better ability to delay smoking. an average of 30 days after baseline
Primary Working Memory Performance 1 NIH Examiner N-back score. The minimum value is 0 and maximum is 90, higher scores indicate a better outcome. Calculated change scores are presented (outcome score at day 30 minus baseline score). Change from baseline score to score at 30 days
Primary Working Memory Performance 2 NIH Examiner Dot Counting Task score. The minimum total score is 0 and the maximum score is 27, higher scores indicate a better outcome. Calculated change scores are presented (outcome score at day 30 minus baseline score). Change from baseline score to score at 30 days
Primary Working Memory Performance 3 Mean End Level Score on Maastricht University Working Memory Tasks. For each scale (i.e. visuospatial, back-digit, and letter-sequencing) the minimum total is 3 and the maximum is 15, higher scores indicate a better outcome. Change from baseline score to score at 30 days
Primary Cigarette Consumption Self reported number of cigarettes smoked daily throughout 60 day study participation, cigarettes per day assessed at outcome reported
Secondary Delay Discounting Discounting Rate on the Monetary Choice Questionnaire, assessed by k (log transformed). Individuals made hypothetical choices between smaller immediate rewards (e.g. $11 today) and larger delayed rewards (e.g. $30 in 7 days) at varying levels of hyperbolic-like discounting. Overall temporal discounting function (k) was assessed; larger values indicate steeper discounting which reflects a worse outcome.
Total score range = 0 - 0.25.
Change from baseline score to score at 30 days
Secondary Cigarette Demand Demand characteristics on the Cigarette Purchase Task. Demand sensitivity indicates sensitivity to change in price, with higher values reflecting higher sensitivity to the monetary reinforcer rather than the substance, thus higher scores reflect a better outcome. Score range = 0 - .100. Change from baseline score to score at 30 days
See also
  Status Clinical Trial Phase
Withdrawn NCT02432066 - Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions Phase 2
Completed NCT03960138 - Examining the Effects of Neural Stimulation on Inhibitory Control and Cigarette Smoking N/A
Recruiting NCT05030272 - Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings N/A
Completed NCT04646668 - Comparative Abuse Liability Among African American and White Smokers N/A
Completed NCT02560324 - Effect of Ramelteon on Smoking Abstinence Phase 2
Completed NCT02347605 - Medicinal Nicotine for Preventing Cue Induced Craving N/A
Completed NCT01625767 - Tobacco Approach Avoidance Training for Adolescent Smokers-1 Phase 2
Completed NCT01428310 - Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke Phase 1
Completed NCT01442753 - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth N/A
Completed NCT01570595 - Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV Phase 1/Phase 2
Terminated NCT01800500 - Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers N/A
Active, not recruiting NCT01539525 - Screening to Augment Referral to Treatment- Project START Phase 2
Completed NCT00967005 - N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers Phase 2
Completed NCT01337817 - A Pilot Study to Evaluate the Efficacy and Safety of Ariva® Silver Wintergreen in Healthy Smokers Phase 1
Active, not recruiting NCT00751660 - Screening Methods in Finding Lung Cancer Early in Current or Former Smokers N/A
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Completed NCT00664261 - Clinical Effort Against Secondhand Smoke (CEASE) Program or Standard Care in Helping Parents Stop Smoking N/A
Completed NCT00218179 - Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1 N/A
Completed NCT01213524 - Nicotine and Sensorimotor Replacement for Smoking in Smokers With Schizophrenia Phase 2
Completed NCT00158158 - Effectiveness of Reducing Smoking in Facilitating Smoking Cessation in Adolescents - 2 Phase 2/Phase 3